Other
Neoplasm by Cause
CI-CAN-00000032Explore in graph →
Non-malignant195 active trials4 approved drugs1 evidence items
- NCIt
- C27933
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000032Explore in graph →
Clinical trials
708 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05284877 | The Organ Transplant Recipient HPV and Skin Cancer Study | recruiting | — | 1,500 | Merete HaedersdalOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT05455086 | Free-Base Nicotine or Nicotine Salt e-Liquids in Current E-Cigarette Smokers, PeloPET Study | completed | N/A | 21 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT02631746 |
| Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma |
| completed |
| Phase 2 |
| 3 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Mar 14, 2025 |
| clinicaltrials |
| NCT05465031 | Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM) | recruiting | Phase 4 | 600 | Silesian Centre for Heart DiseasesOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | terminated | Phase 1 | 26 | Viracta Therapeutics, Inc.INDUSTRY | 8 | Mar 12, 2025 | clinicaltrials |
| NCT03157167 | An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS) | completed | Phase 1 | 15 | Navidea BiopharmaceuticalsINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT05417932 | A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma(TCR-T) | recruiting | Phase 1 / Phase 2 | 46 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 3 | Feb 18, 2025 | clinicaltrials |
| NCT05829629 | Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | recruiting | Phase 1 | 20 | BlueSky Immunotherapies GmbHINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT04102150 | Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma | completed | Phase 2 | 25 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04871490 | Improving Detection and Early Action for HPV-positive Oropharynx Cancer(IDEA-HPV) | completed | N/A | 40 | Brigham and Women's HospitalOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06268535 | Identification of Anticancer Drugs Associated With Cancer Therapy-related Cardiac Dysfunction: a Pharmacovigilance Study | completed | — | 36,580,288 | University Hospital, CaenOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06454175 | A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years | unknown | Phase 1 | 72 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 6, 2025 | clinicaltrials |
| NCT05453773 | Hookah Additive Research to Inform Product Standards(HARPS) | completed | N/A | 54 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06745154 | Evaluating the Impact of Quitting Using Executive Function Strategy Training (QUEST) on Smoking Cessation in Homeless Young Adult Smokers | completed | N/A | 27 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05831540 | Clinical Decision Support Tools to Increase Human Papillomavirus (HPV) Vaccination in Adolescents in Pharmacies | terminated | N/A | 31 | Fred Hutchinson Cancer CenterOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT05321992 | Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand(eCHEC) | recruiting | N/A | 480 | McMaster UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06339684 | HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis(HPVImmuno) | unknown | — | 120 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05882305 | KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial | withdrawn | Early Phase 1 | 0 | Kousai Bio Co., Ltd.OTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT02532231 | Nivolumab in AML in Remission at High Risk for Relapse | completed | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT05202782 | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma | active not recruiting | Phase 2 | 24 | Northwestern UniversityOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT06617000 | A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related | recruiting | Phase 1 | 38 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06099418 | Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer. | withdrawn | Phase 2 | 0 | Nykode Therapeutics ASAINDUSTRY | 0 | Sep 20, 2024 | clinicaltrials |
| NCT06598176 | Developing a Combined Molecular Screening and Triage Test for Cervical Cancer in Self-samples(COMBISCREEN) | recruiting | N/A | 100 | Universiteit AntwerpenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06578871 | Surgery and Reducing Ionizing Radiation of the Unknown Primary(SUPERIOR) | not yet recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 2 | Sep 3, 2024 | clinicaltrials |
| NCT05783167 | Self-collected Vaginal and Urine Samples in HIV-positive Women | completed | — | 502 | University of AarhusOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT06544720 | SCG142 TCR-T Cells for Human Papillomavirus-Associated Carcinomas | recruiting | Phase 1 | 18 | The Affiliated Hospital of Qingdao UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT04014374 | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab | recruiting | — | 150 | Kyowa Kirin, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT05847673 | Avatar-Led Digital Therapeutic for Aiding Smoking Cessation in Sexual and Gender Minority Young Adults | completed | N/A | 125 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | terminated | Phase 1 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT03316274 | Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma | completed | Early Phase 1 | 12 | University of California, San FranciscoOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT02029430 | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | completed | Phase 2 | 15 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT02199184 | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia | completed | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05236894 | Appeal of Nicotine Pouches Versus Cigarettes in the Ohio Appalachia Population | completed | Early Phase 1 | 55 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT04444869 | Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer(ENID) | unknown | Phase 2 | 28 | University of Missouri-ColumbiaOTHER | 1 | May 17, 2024 | clinicaltrials |
| NCT05411107 | Oral Iloprost for the Prevention of Lung Cancer In Former Smokers | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | May 17, 2024 | clinicaltrials |
| NCT05864924 | A Phase 1 Study of BRG01 in Subjects With Relapsed/Metastatic Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma | completed | Phase 1 | 14 | BioSyngen Pte LtdINDUSTRY | 1 | May 8, 2024 | clinicaltrials |
| NCT05081141 | HHV8 and Solid Organ Transplantation | unknown | — | 250 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT03993106 | A Study of sEphB4-HSA in Kaposi Sarcoma | unknown | Phase 2 | 65 | Vasgene Therapeutics, IncINDUSTRY | 1 | May 2, 2024 | clinicaltrials |
| NCT01626664 | KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL) | completed | Phase 2 | 71 | Kyowa Kirin, Inc.INDUSTRY | 6 | Apr 25, 2024 | clinicaltrials |
| NCT06376435 | A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia | unknown | — | 500 | Hebei Medical University Fourth HospitalOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT03601507 | Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer | terminated | Phase 2 | 9 | University of ArizonaOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT00339937 | Studies of Human Herpesvirus 8 and Kaposi's Sarcoma in Sicily | completed | — | 4,622 | National Cancer Institute (NCI)NIH | 1 | Mar 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 1, 2025source: clinicaltrials